Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


August 31, 2015 3:37 AM ET

Pharmaceuticals

Company Overview of MedImmune, LLC

Company Overview

MedImmune, LLC, a biologics research and development company, researches, develops, and explores medicines for unmet medical needs across therapeutic areas, including respiratory, inflammation, and autoimmunity; cardiovascular and metabolic disease; oncology; neuroscience; and infection and vaccines worldwide. It offers Synagis (palivizumab), a monoclonal antibody to prevent serious lower respiratory tract disease; FluMist Quadrivalent (Influenza Vaccine Live, Intranasal), a quadrivalent influenza vaccine; and Trivalent FluMist (T/LAIV), a live attenuated influenza vaccine. The company was incorporated in 1987 and is based in Gaithersburg, Maryland with locations in Mountain View, Santa Clar...

One MedImmune Way

Gaithersburg, MD 20878

United States

Founded in 1987

2,359 Employees

Phone:

301-398-0000

Fax:

301-527-4200

Key Executives for MedImmune, LLC

Vice President of Finance
Chief Operating Officer
Vice President, Head of Antibody Discovery and Protein Engineering and Global Head of Technology
Senior Vice President of Biopharmaceutical Development
Age: 60
Executive Vice President
Compensation as of Fiscal Year 2015.

MedImmune, LLC Key Developments

Advaxis, Inc and MedImmune Commence Enrollment in Phase I/II Study of Axalimogene Filolisbac in Combination With Durvalumab

Advaxis, Inc. announced that enrollment has commenced in a phase I/II clinical trial of axalimogene filolisbac (ADXS-HPV), Advaxis's investigational Lm Technology™ immunotherapy, in combination with MedImmune's investigational anti-PD-L1 immune checkpoint inhibitor, durvalumab (MEDI4736), for the treatment of patients with advanced, recurrent or refractory human papillomavirus (HPV)-associated cervical cancer and HPV-associated head and neck cancer. The two-part, open-label Phase I/II study is designed to evaluate the safety and efficacy of axalimogene filolisbac as a monotherapy and in combination with durvalumab in approximately 66 patients. Phase I is a dose-confirmation combination study with axalimogene filolisbac and durvalumab, which is expected to establish the maximum tolerated dose. The Phase II portion of the study will randomize patients to receive axalimogene filolisbac monotherapy, durvalumab monotherapy, or the combination.

MedImmune Teams Up With Mirati Therapeutics on Lung Cancer Trials

MedImmune and Mirati Therapeutics are collaborating on early-phase clinical trials to evaluate the safety and efficacy of investigational drugs in patients with non-small cell lung cancer. The trials, expected to begin next year, will combine MedImmune's durvalumab, an anti-PDL1 immune checkpoint inhibitor, with Mirati's mocetinostat, a spectrum-selective histone deacetylase inhibitor. Under the agreement, Mirati will conduct and fund the initial trials and MedImmune will supply durvalumab. If those studies show positive results, Medimmune will have an exclusive period to negotiate a commercial license for the combination. On their own, mocetinostat has FDA orphan drug designation as a treatment for diffuse large B-cell lymphoma and durvalumab has been accelerated into Phase 3 clinical development in NSCLC and head and neck cancers.

Medimmune Appoints Christopher Rhodes as Head of Cardiovascular, Metabolic Disease Research

MedImmune announced that Christopher Rhodes, Ph.D., has joined the company as Vice President, Cardiovascular and Metabolic Disease (CVMD) Research. Dr. Rhodes will be responsible for developing and growing MedImmune's research base in CVMD in both the US and UK, and contributing to the product development goals and vision across the CVMD therapeutic area. Dr. Rhodes joins MedImmune from the University of Chicago, where he was Research Director at the Kovler Diabetes Center, the Kovler Family Professor of Endocrinology, and Chair of the Committee on Molecular Metabolism & Nutrition and Biomedical Sciences Cluster of the Biological Sciences Division.

Similar Private Companies By Industry

Company Name Region
RPI Finance Trust United States
Ischemix, Inc. United States
Receptor Logic, Inc. United States
Amarin Pharmaceuticals, Inc. United States
Pernix Sleep, Inc. United States

Recent Private Companies Transactions

Type
Date
Target
Merger/Acquisition
November 4, 2014
Definiens AG
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact MedImmune, LLC, please visit www.medimmune.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.